NUMD — Nu-Med Plus Share Price
0.000.00%
Last trade - 00:00- $4.18m
- $4.28m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nu-Med Plus, Inc. is a medical device company principally engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and later-stage quality medical devices. It focuses on the creation of a nitric oxide (NO) generating formulation, a hospital bedside NO delivery system, a clinical unit for use in medical clinics and rehabilitation centers and a mobile rechargeable device to deliver nitric oxide gas to offer solutions to hospitals, health systems and the medical community throughout the world. Hospital NO Unit delivers a continuous intra-breath concentration of therapeutic NO to patients who are on a ventilator in a hospital setting. The Clinical Delivery System is a simplified version of the hospital unit. Portable Delivery System delivers NO to the patient at prescribed intervals for 24 hours per day at controlled doses by means of a nasal cannula or a face mask. Reagent Delivery offers a range of concentrations and flow rates of NO.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 25th, 2011
- Public Since
- August 2nd, 2013
- No. of Shareholders
- 155
- No. of Employees
- 2
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 83,548,469
- Address
- 455 East 500 South, Suite #203, SALT LAKE CITY, 84111
- Web
- https://yourspaceamerica.com/
- Phone
- +1 8017463570
- Auditors
- Fruci & Associates II,PLLC
Upcoming Events for NUMD
Q2 2025 Nu-Med Plus Inc Earnings Release
Similar to NUMD
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
What is the Nu-Med Plus share price?
As of Today at 22:24 UTC, shares in Nu-Med Plus are trading at $0.05. This share price information is delayed by 15 minutes.
How has the Nu-Med Plus share price performed this year?
Shares in Nu-Med Plus last closed at $0.05 and the price had moved by -25.26% over the past 365 days. In terms of relative price strength the Nu-Med Plus share price has underperformed the S&P500 Index by -30.7% over the past year.
What are the analyst and broker recommendations for Nu-Med Plus?
There is no consensus recommendation for this security.
Find out moreWhat is the Nu-Med Plus dividend yield?
Nu-Med Plus does not currently pay a dividend.
Does Nu-Med Plus pay a dividend?
Nu-Med Plus does not currently pay a dividend.
When does Nu-Med Plus next pay dividends?
Nu-Med Plus does not currently pay a dividend.
How do I buy Nu-Med Plus shares?
To buy shares in Nu-Med Plus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nu-Med Plus?
As of the previous close price of $0.05, shares in Nu-Med Plus had a market capitalisation of $4.18m.
Where are Nu-Med Plus shares listed?
Here are the trading details for Nu-Med Plus:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NUMD
What kind of share is Nu-Med Plus?
Based on an overall assessment of its quality, value and momentum Nu-Med Plus is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nu-Med Plus share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Nu-Med Plus share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nu-Med Plus. Over the past six months, its share price has outperformed the S&P500 Index by +181.64%.
As of the last closing price of $0.05, shares in Nu-Med Plus were trading +4.73% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nu-Med Plus PE Ratio?
The Nu-Med Plus PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nu-Med Plus?
Nu-Med Plus' management team is headed by:
- Jeffrey Robins - CEO
- Keith Merrell - CFO
- Brett Earl - VPR